## Francesc J Moreso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5873328/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Trasplante renal de donante vivo. Análisis de situación y hoja de ruta. Nefrologia, 2022, 42, 85-93.	0.4	1
2	Bioavailability of onceâ€daily tacrolimus formulations used in clinical practice in the management of <i>De Novo</i> kidney transplant recipients: the better study. Clinical Transplantation, 2022, 36, e14550.	1.6	7
3	A comprehensive assessment of long-term SARS-CoV-2–specific adaptive immune memory inÂconvalescent COVID-19 Solid Organ Transplant recipients. Kidney International, 2022, 101, 1027-1038.	5.2	10
4	Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study). Microbiology Spectrum, 2022, 10, e0178421.	3.0	16
5	High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation. Clinical and Translational Science, 2022, 15, 1544-1555.	3.1	7
6	MO1017: Induction Immunosuppression and Outcome in Early Kidney Transplant Recipients with Covid-19. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
7	Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers. CKJ: Clinical Kidney Journal, 2021, 14, 482-491.	2.9	12
8	HIV-positive deceased donor–to–HIV-positive recipient kidney transplantation: The HOPE must go on. American Journal of Transplantation, 2021, 21, 1683-1684.	4.7	3
9	COVID-19 in transplant recipients: The Spanish experience. American Journal of Transplantation, 2021, 21, 1825-1837.	4.7	156
10	Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism. Journal of Clinical Medicine, 2021, 10, 141.	2.4	7
11	Change in Estimated GFR and Risk of Allograft Failure in Patients Diagnosed With Late Active Antibody-mediated Rejection Following Kidney Transplantation. Transplantation, 2021, 105, 648-659.	1.0	22
12	Kidney transplantation and COVID-19 renal and patient prognosis. CKJ: Clinical Kidney Journal, 2021, 14, i21-i29.	2.9	32
13	Impact of HLA Mismatching on Early Subclinical Inflammation in Low-Immunological-Risk Kidney Transplant Recipients. Journal of Clinical Medicine, 2021, 10, 1934.	2.4	9
14	Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. American Journal of Transplantation, 2021, 21, 2573-2582.	4.7	53
15	La fragilidad en candidatos a trasplante renal. Nefrologia, 2021, 41, 237-243.	0.4	4
16	Frailty and kidney transplant candidates. Nefrologia, 2021, 41, 237-243.	0.4	8
17	A Specific Tubular ApoA-I Distribution Is Associated to FSCS Recurrence after Kidney Transplantation. Journal of Clinical Medicine, 2021, 10, 2174.	2.4	2
18	MO298A SPECIFIC TUBULAR APOA-I DISTRIBUTION IS ASSOCIATED TO FSGS RECURRENCE AFTER KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0

Francesc J Moreso

#	Article	IF	CITATIONS
19	Recomendaciones en el seguimiento del trasplantado renal. FMC Formacion Medica Continuada En Atencion Primaria, 2021, 28, 289-294.	0.0	0
20	Clinical Relevance of Corticosteroid Withdrawal on Graft Histological Lesions in Low-Immunological-Risk Kidney Transplant Patients. Journal of Clinical Medicine, 2021, 10, 2005.	2.4	6
21	COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?. Transplantation, 2021, 105, 2146-2155.	1.0	25
22	Longâ€ŧerm effects of COVIDâ€19 in solid organ transplantation recipients. Transplant Infectious Disease, 2021, 23, e13677.	1.7	2
23	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney International, 2021, 100, 196-205.	5.2	95
24	Tocilizumab en el tratamiento del rechazo humoral crónico activo resistente a terapia estándar. Nefrologia, 2021, , .	0.4	0
25	Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. Kidney International Reports, 2021, 6, 2305-2315.	0.8	26
26	Reconciling shortâ€ŧerm clinical and Immunological outcomes of SARS oVâ€2 vaccination in Solid Organ Transplant recipients. American Journal of Transplantation, 2021, , .	4.7	6
27	COVID-19 in Solid Organ Transplantation: A Matched Retrospective Cohort Study and Evaluation of Immunosuppression Management. Transplantation, 2021, 105, 138-150.	1.0	50
28	Protocol for Optimizing the Use of Kidneys From Donors With Seropositivity for Hepatitis C Virus in Seronegative Recipients. Transplantation Proceedings, 2021, 53, 2655-2658.	0.6	3
29	Deciphering transplant outcomes of expanded kidney allografts donated after controlled circulatory death in the current transplant era. A call for caution. Transplant International, 2021, 34, 2494-2506.	1.6	7
30	Surgeon preimplantation macroscopic graft appraisal improves risk stratification of deceased kidney donors: a prospective study. Minerva Urology and Nephrology, 2021, , .	2.5	4
31	Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study. American Journal of Transplantation, 2020, 20, 3030-3041.	4.7	78
32	P0349A MISSPROCESSED FORM OF APOLIPOPROTEIN A-I IS SPECIFICALLY ASSOCIATED TO RECURRENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
33	The keys to control a COVID-19 outbreak in a haemodialysis unit. CKJ: Clinical Kidney Journal, 2020, 13, 542-549.	2.9	45
34	A Rejection Gene Expression Score in Indication and Surveillance Biopsies Is Associated with Graft Outcome. International Journal of Molecular Sciences, 2020, 21, 8237.	4.1	1
35	P1741TACROLIMUS FAST METABOLIZERS SHOW A HIGHER PROGRESSION OF INTERTITIAL FIBROSIS AND TUBULAR ATROPHY DURING THE FIRST YEAR AFTER RENAL TRASPLANTATION. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
36	Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial. Clinical Infectious Diseases, 2020, 71, 2375-2385.	5.8	29

#	Article	IF	CITATIONS
37	A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis. Scientific Reports, 2020, 10, 1159.	3.3	10
38	Transcriptome Analysis in Renal Transplant Biopsies Not Fulfilling Rejection Criteria. International Journal of Molecular Sciences, 2020, 21, 2245.	4.1	3
39	Perfil de personalidad en pacientes con trasplante renal: el modelo alternativo de los cinco factores. Revista Colombiana De NefrologÃa, 2020, 7, 36-43.	0.1	0
40	PROTOCOL BASED ON HEPATITIS C VIRUS NUCLEIC ACID TESTING TO OPTIMIZE RENAL TRANSPLANT FROM SEROPOSITIVE DONORS TO SERONEGATIVE RECIPIENTS. AN EUROPEAN EXPERIENCE. Transplantation, 2020, 104, S267-S267.	1.0	0
41	SuO002LOW POTASSIUM LEVELS AND MORTALITY IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
42	FP205APOLIPOPROTEIN A-IB AS BIOMARKER OF FSGS RECURRENCE AFTER KIDNEY TRANSPLANTATION: DIAGNOSTIC PERFORMANCE AND ASSESSMENT OF ITS PROGNOSTIC VALUE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
43	Early outcomes of kidney transplantation from elderly donors after circulatory death (GEODAS) Tj ETQq1 1 0.784	1314 rgBT	/Overlock 10
44	Prediabetes is a risk factor for cardiovascular disease following renal transplantation. Kidney International, 2019, 96, 1374-1380.	5.2	28
45	SP773Evaluating adherence to immunosuppressive drugs through Trackyourmed® an innovative QR code-scanner app in renal transplantation: Preliminary results from I-COM trial. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
46	FP763Endothelial progenitor cells and carotid plaque progression in kidney transplants. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
47	Complement Activation and Thrombotic Microangiopathies. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1719-1732.	4.5	57
48	Vitamin D deficiency in solidâ€organ transplant recipients from a Spanish Mediterranean population. Clinical and Experimental Dermatology, 2019, 44, e103-e109.	1.3	5
49	Antibiotic Treatment Versus No Treatment for Asymptomatic Bacteriuria in Kidney Transplant Recipients: A Multicenter Randomized Trial. Open Forum Infectious Diseases, 2019, 6, ofz243.	0.9	26
50	Kidney transplant from controlled donors following circulatory death: Results from the GEODAS-3 multicentre study. Nefrologia, 2019, 39, 151-159.	0.4	2
51	Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study. Transplant International, 2019, 32, 710-716.	1.6	30
52	231.3: The final frontier: Saving lives through biovigilance Transplantation, 2019, 103, S40-S41.	1.0	0
53	Is antibody-mediated rejection in kidney transplant recipients a risk factor for developing cytomegalovirus or BK virus infection? Results from a case-control study. Journal of Clinical Virology, 2019, 110, 45-50.	3.1	2
54	Apolipoprotein A-lb as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value - a multi-centre cohort study. Transplant International, 2019, 32, 313-322.	1.6	22

#	Article	IF	CITATIONS
55	Trasplante renal con órganos procedentes de donación tras parada circulatoria controlada: resultados del estudio multicéntrico GEODAS-3. Nefrologia, 2019, 39, 151-159.	0.4	5
56	Cutaneous infections by dematiaceous opportunistic fungi: Diagnosis and management in 11 solid organ transplant recipients. Mycoses, 2019, 62, 121-127.	4.0	28
57	Relationships between iron dose, hospitalizations and mortality in incident haemodialysis patients: a propensity-score matched approach. Nephrology Dialysis Transplantation, 2018, 33, 160-170.	0.7	7
58	Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients. Kidney International Reports, 2018, 3, 122-132.	0.8	6
59	Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. American Journal of Transplantation, 2018, 18, 927-935.	4.7	134
60	FP607EFFICAY AND COST SAVINGS OF THE NEW IRON-BASED PHOSPHATE BINDER IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i246-i247.	0.7	0
61	Apolipoprotein A-Ib as Biomarker of FSGS Recurrence After Kidney Transplantation. Transplantation, 2018, 102, S8-S9.	1.0	0
62	Empathy assessment in living kidney donors. Nefrologia, 2018, 38, 570-572.	0.4	0
63	Evaluación de la empatÃa en donante vivo de riñón. Nefrologia, 2018, 38, 570-572.	0.4	Ο
64	Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treatment Reviews, 2018, 69, 164-176.	7.7	35
65	Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus. Kidney International Reports, 2018, 3, 1304-1315.	0.8	47
66	Prevalence of Chagas Disease among Solid Organ–Transplanted Patients in a Nonendemic Country. American Journal of Tropical Medicine and Hygiene, 2018, 98, 742-746.	1.4	17
67	Health-related behaviours after 1 year of renal transplantation. Journal of Health Psychology, 2017, 22, 505-514.	2.3	7
68	Successful multiple organ donation after donor brain death due to <i><scp>A</scp>ctinomyces israelii</i> meningitis. Transplant Infectious Disease, 2017, 19, e12711.	1.7	1
69	Hemodiafiltration Reduces All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients: A Propensity-Matched Cohort Study. American Journal of Nephrology, 2017, 46, 288-297.	3.1	31
70	TO019CONTROLLED RANDOMIZED STUDY COMPARING PARICALCITOL WITH CALCIFEDIOL FOR TREATING HYPERPARATHYROIDISM IN KIDNEY ALLOGRAFT RECIPIENTS. Nephrology Dialysis Transplantation, 2017, 32, iii86-iii86.	0.7	0
71	Calidad de vida relacionada con la salud en el trasplante renal: seguimiento longitudinal a 2 años. Medicina ClÃnica, 2017, 149, 114-118.	0.6	12
72	Health literacy and chronic kidney disease. Nefrologia, 2017, 37, 115-117.	0.4	4

#	Article	IF	CITATIONS
73	Papel de los fármacos inhibidores de mTOR en la prevención del cáncer cutáneo no melanoma en los pacientes receptores de un trasplante de órgano sólido. Piel, 2017, 32, 531-534.	0.0	0
74	Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. Transplant International, 2017, 30, 1119-1131.	1.6	10
75	Health related quality of life in renal transplantation: 2 years of longitudinal follow-up. Medicina ClÃnica (English Edition), 2017, 149, 114-118.	0.2	6
76	Alfabetización en salud y enfermedad renal crónica. Nefrologia, 2017, 37, 115-117.	0.4	5
77	Fascin-1 is released from proximal tubular cells in response to calcineurin inhibitors (CNIs) and correlates with isometric vacuolization in kidney transplanted patients. American Journal of Translational Research (discontinued), 2017, 9, 4173-4183.	0.0	3
78	SP588LOOKING FOR CUTOFF VALUES OF TRANSAMINASES AND OTHER RELATED FACTORS WITH THE HCV INFECTION IN HD PATIENTS. Nephrology Dialysis Transplantation, 2016, 31, i290-i290.	0.7	0
79	MP583SEASONAL PROFILE OF IPTH AND VITAMIN D IN CHRONIC HEMODIALYSIS PATIENTS: ANALYSIS OF THE SPANISH FRESENIUS MEDICAL CARE CLINICS. Nephrology Dialysis Transplantation, 2016, 31, i535-i535.	0.7	0
80	ESHOL study reanalysis: All-cause mortality considered by competing risks and time-dependent covariates for renal transplantation. Nefrologia, 2016, 36, 156-163.	0.4	11
81	Hemodialysis patients receiving a greater Kt dose than recommended have reduced mortality and hospitalization risk. Kidney International, 2016, 90, 1332-1341.	5.2	33
82	Reanálisis del estudio ESHOL: mortalidad por todas las causas considerando riesgos de competición y tiempo-dependientes para trasplante renal. Nefrologia, 2016, 36, 156-163.	0.4	18
83	Inflammation and Atherosclerosis Are Associated With Hypertension in Kidney Transplant Recipients. Journal of Clinical Hypertension, 2015, 17, 963-969.	2.0	16
84	Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice. Transplant International, 2015, 28, 1042-1054.	1.6	29
85	FP895USEFULNESS OF KIDNEY PREIMPLANTATION BIOPSIES FROM DECEASED DONORS FOR KIDNEY TRANSPLANT ALLOCATION. Nephrology Dialysis Transplantation, 2015, 30, iii375-iii375.	0.7	0
86	FP898CAROTID ATHEROSCLEROSIS PROGRESSION AND REVERSE DIPPER PATTERN IN KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2015, 30, iii376-iii376.	0.7	0
87	FP832TOTAL INFLAMMATION SCORE IN LATE RENAL ALLOGRAFT BIOPSIES FOR CAUSE IS AN INDEPENDENT PREDICTOR OF GRAFT FAILURE. Nephrology Dialysis Transplantation, 2015, 30, iii355-iii355.	0.7	0
88	FP850TACROLIMUS TROUGH SERUM LEVELS ARE ASSOCIATED WITH SUBCLINICAL INFLAMMATION IN THREE MONTH SURVEILLANCE BIOPSIES PERFORMED IN STABLE RENAL TRANSPLANTS. Nephrology Dialysis Transplantation, 2015, 30, iii361-iii361.	0.7	0
89	SP804THE CONTRIBUTION OF INFLAMMATION AND ATHEROSCLEROSIS TO HYPERTENSION IN KIDNEY TRANSPLANTS. Nephrology Dialysis Transplantation, 2015, 30, iii643-iii643.	0.7	0
90	C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II. Nefrologia, 2015, 35, 80-6.	0.4	1

#	Article	IF	CITATIONS
91	The Interplay between Inflammation and Fibrosis in Kidney Transplantation. BioMed Research International, 2014, 2014, 1-9.	1.9	49
92	The reproducibility and predictive value on outcome of renal biopsies from expanded criteria donors. Kidney International, 2014, 85, 1161-1168.	5.2	126
93	Comparing transplant glomerulopathy in the absence of C4d deposition and donorâ€specific antibodies to chronic antibodyâ€mediated rejection. Clinical Transplantation, 2014, 28, 1148-1154.	1.6	18
94	Hypertension in Chronic Kidney Disease. Transplantation, 2014, 98, 537-542.	1.0	20
95	UreteropielostomÃa con vÃa nativa en el tratamiento de la uropatÃa obstructiva en el trasplante renal adulto. Experiencia y posibilidades técnicas. Actas Urológicas Españolas, 2014, 38, 552-556.	0.7	1
96	Innate immunity in renal transplantation: The role of mannose-binding lectin. Transplantation Reviews, 2014, 28, 21-25.	2.9	12
97	Low serum mannose-binding lectin levels are associated with inflammation and apoptosis in early surveillance allograft biopsies. Transplant Immunology, 2014, 31, 152-156.	1.2	6
98	Gene expression signature of tolerance and lymphocyte subsets in stable renal transplants: Results of a cross-sectional study. Transplant Immunology, 2014, 31, 11-16.	1.2	26
99	Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. Nephrology Dialysis Transplantation, 2013, 28, 213-220.	0.7	82
100	Should high-flux hemodialysis be replaced by online hemodiafiltration for treating end-stage renal disease patients?. Journal of Comparative Effectiveness Research, 2013, 2, 347-349.	1.4	1
101	High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2013, 24, 487-497.	6.1	595
102	Has patient survival following renal transplantation improved in the era of modern immunosuppression?. Nefrologia, 2013, 33, 171-80.	0.4	15
103	Has the survival of the graft improved after renal transplantation in the era of modern immunosuppression?. Nefrologia, 2013, 33, 14-26.	0.4	20
104	Reverse dipper pattern of blood pressure at 3 months is associated with inflammation and outcome after renal transplantation. Nephrology Dialysis Transplantation, 2012, 27, 2089-2095.	0.7	41
105	Early Subclinical Rejection as a Risk Factor for Late Chronic Humoral Rejection. Transplantation, 2012, 93, 41-46.	1.0	92
106	Is adiponectin a marker of preclinical atherosclerosis in kidney transplantation?. Clinical Transplantation, 2012, 26, 259-266.	1.6	7
107	Contribution of Anemia and Hypertension to Left Ventricular Hypertrophy During the Initial 2 Years After Renal Transplantation. Transplantation Proceedings, 2011, 43, 2199-2204.	0.6	6
108	Mean Glomerular Volume After Renal Transplantation in Patients Receiving Sirolimus and Cyclosporine A Compared With Elimination of Cyclosporine A at 3 Months. Transplantation, 2011, 91, e5-e6.	1.0	1

#	Article	IF	CITATIONS
109	Chronic Renal Allograft Damage: Existing Challenges. Transplantation, 2011, 91, S4-S25.	1.0	23
110	Estimation of renal allograft half-life: fact or fiction?. Nephrology Dialysis Transplantation, 2011, 26, 3013-3018.	0.7	15
111	Subclinical rejection in renal transplants is associated with low serum mannose-binding lectin levels. Kidney International Supplements, 2011, 1, 36-39.	14.2	6
112	Design and patient characteristics of ESHOL study, a Catalonian prospective randomized study. Journal of Nephrology, 2011, 24, 196-202.	2.0	18
113	Improvement in late renal allograft survival between 1990 and 2002 in Spain: results from a multicentre case-control study. Transplant International, 2010, 23, 907-13.	1.6	11
114	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain. CKJ: Clinical Kidney Journal, 2010, 3, ii21-ii25.	2.9	3
115	Early statin use is an independent predictor of long-term graft survival. CKJ: Clinical Kidney Journal, 2010, 3, ii26-ii31.	2.9	5
116	Renal transplant outcomes in Spain. CKJ: Clinical Kidney Journal, 2010, 3, ii1-ii1.	2.9	2
117	Intragraft Expression of the IL-10 Gene Is Up-Regulated in Renal Protocol Biopsies with Early Interstitial Fibrosis, Tubular Atrophy, and Subclinical Rejection. American Journal of Pathology, 2010, 176, 1696-1704.	3.8	20
118	Low Serum Mannose-Binding Lectin as a Risk Factor for New Onset Diabetes Mellitus After Renal Transplantation. Transplantation, 2009, 88, 272-278.	1.0	26
119	A Novel Risk Score for Mortality in Renal Transplant Recipients Beyond the First Posttransplant Year. Transplantation, 2009, 88, 803-809.	1.0	45
120	Poly[ADP-Ribose] Polymerase-1 Expression Is Related To Cold Ischemia, Acute Tubular Necrosis, and Delayed Renal Function In Kidney Transplantation. PLoS ONE, 2009, 4, e7138.	2.5	13
121	Presence of FoxP3+ Regulatory T Cells Predicts Outcome of Subclinical Rejection of Renal Allografts. Journal of the American Society of Nephrology: JASN, 2008, 19, 2020-2026.	6.1	141
122	Fluvastatin in the Prevention of Renal Transplant Vasculopathy: Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Transplantation, 2008, 86, 82-87.	1.0	24
123	Graft dysfunction and cardiovascular riskan unholy alliance. Nephrology Dialysis Transplantation, 2007, 22, 699-702.	0.7	7
124	Achieving Donor-Specific Hyporesponsiveness Is Associated with FOXP3+ Regulatory T Cell Recruitment in Human Renal Allograft Infiltrates. Journal of Immunology, 2007, 179, 4901-4909.	0.8	143
125	Immunophenotype of Infiltrating Cells in Protocol Renal Allograft Biopsies From Tacrolimus-Versus Cyclosporine-Treated Patients. Transplantation, 2007, 83, 649-652.	1.0	16
126	Sevelamer Hydrochloride in Peritoneal Dialysis Patients: Results of a Multicenter Cross-Sectional Study. Peritoneal Dialysis International, 2007, 27, 697-701.	2.3	15

#	Article	IF	CITATIONS
127	Cholesterol embolism: Still an unrecognized entity with a high mortality rate. Journal of the American Academy of Dermatology, 2006, 55, 786-793.	1.2	61
128	Relationship Between Subclinical Rejection and Genotype, Renal Messenger RNA, and Plasma Protein Transforming Growth Factor–β1 Levels. Transplantation, 2006, 81, 1463-1466.	1.0	13
129	Evaluation of pre-implantation kidney biopsies: Comparison of Banff criteria to a morphometric approach. Kidney International, 2005, 67, 1595-1600.	5.2	86
130	Risk factors associated with the deterioration of renal function after kidney transplantation. Kidney International, 2005, 68, S113-S117.	5.2	18
131	Incidence of C4d Stain in Protocol Biopsies from Renal Allografts: Results from a Multicenter Trial. American Journal of Transplantation, 2005, 5, 1050-1056.	4.7	140
132	Resistive index and chronic allograft nephropathy evaluated in protocol biopsies as predictors of graft outcome. Nephrology Dialysis Transplantation, 2005, 20, 2511-2516.	0.7	29
133	Angiotensin Converting Enzyme Genotype and Chronic Allograft Nephropathy in Protocol Biopsies. Journal of the American Society of Nephrology: JASN, 2004, 15, 2229-2236.	6.1	11
134	Recipient age as a determinant factor of patient and graft survival. Nephrology Dialysis Transplantation, 2004, 19, iii16-iii20.	0.7	7
135	Glomerular Enlargement Assessed by Paired Donor and Early Protocol Renal Allograft Biopsies. American Journal of Transplantation, 2004, 4, 650-654.	4.7	24
136	Splicing alterations in human renal allografts: detection of a new splice variant of protein kinase Par1/Emk1 whose expression is associated with an increase of inflammation in protocol biopsies of transplanted patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1689, 58-65.	3.8	8
137	Baseline Immunosuppression is Associated with Histological Findings in Early Protocol Biopsies. Transplantation, 2004, 78, 1064-1068.	1.0	50
138	Structural and functional correlations in stable renal allografts. American Journal of Kidney Diseases, 2003, 41, 1065-1073.	1.9	9
139	Estimation of Total Glomerular Number in Stable Renal Transplants. Journal of the American Society of Nephrology: JASN, 2003, 14, 2662-2668.	6.1	93
140	Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation, 2003, 76, 969-973.	1.0	192
141	Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney International, 2002, 61, 727-733.	5.2	109
142	Serial Protocol Biopsies to Quantify the Progression of Chronic Transplant Nephropathy in Stable Renal Allografts. American Journal of Transplantation, 2001, 1, 82-88.	4.7	74
143	PROTOCOL RENAL ALLOGRAFT BIOPSIES AND THE DESIGN OF CLINICAL TRIALS AIMED TO PREVENT OR TREAT CHRONIC ALLOGRAFT NEPHROPATHY1. Transplantation, 2000, 69, 1849-1855.	1.0	98
144	RECIPIENT BODY SURFACE AREA AS A PREDICTOR OF POSTTRANSPLANT RENAL ALLOGRAFT EVOLUTION1. Transplantation, 1998, 65, 671-676.	1.0	66

#	Article	IF	CITATIONS
145	Early protocol renal allograft biopsies and graft outcome. Kidney International, 1997, 51, 310-316.	5.2	223
146	Quantification of interstitial chronic renal damage by means of texture analysis. Kidney International, 1994, 46, 1721-1727.	5.2	29
147	Nonadherence to immunosuppression: challenges and solutions. Transplant Research and Risk Management, 0, , 27.	0.7	5
148	SARS-CoV-2 in Kidney Transplant Recipients: A Multicentric Prospective Cohort Study. SSRN Electronic Journal, 0, , .	0.4	1
149	Prediabetes and Cardiovascular Disease After Renal Transplantation. SSRN Electronic Journal, 0, , .	0.4	0
150	Induction immunosuppression and outcome in kidney transplant recipients with early COVID-19 after transplantation. CKJ: Clinical Kidney Journal, 0, , .	2.9	1